Due to rising antimicrobial resistance, the treatment of complicated UTIs and acute pyelonephritis is becoming more difficult ...
GSK and Spero Therapeutics' oral cabapenem, tebipenem HBr, has become the first antibiotic in the class to show efficacy in a ...
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of ...
GSK & Spero announce positive PIVOT-PO phase III trial of tebipenem HBr, an investigational oral treatment for complicated urinary tract infections: London, UK Wednesday, October ...
Under the terms of a deal that rescued the once-rejected tebipenem HBr, GSK will file for approval of the oral antibiotic. Back in 2022, after the FDA requested another phase 3 trial and denied ...
New data presented at IDWeek 2025 by Japanese drugmaker Shionogi highlight the real-world effectiveness of cefiderocol in ...
Based on these findings, the Independent Data Monitoring Committee recommended the trial stop early. Topline data were announced from a phase 3 trial evaluating tebipenem pivoxil hydrobromide (HBr) in ...
The combination of cefepime, a cephalosporin antibiotic, and enmetazobactam, a novel extended-spectrum β-lactamase inhibitor (Exblifep; Allecra Therapeutics) was found to be superior to ...
The European Medicines Agency (EMA) has recommended that the medicinal product cefepime-enmetazobactam (Exblifep) should be granted a marketing authorization for treating adults with urinary tract ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback